Soligenix demonstrates thermostabilization success

Soligenix, Inc., a development stage pharmaceutical company, announced on Monday that it has demonstrated positive results from preclinical studies into its proprietary vaccine thermostabilization technology.

The results indicate that the company is able to produce stable vaccine formulations using protein immunogens, adjuvants and other components that typically wouldn't be able to withstand long variations in temperature. The studies used Soligenix's aluminum-adjuvanted ricin vaccine, RiVax.

"We are very excited about these results as the achievement of extended stability under elevated temperature represents a significant step forward in vaccine technology," Robert N. Brey, the chief scientific officer at Soligenix, said. "These studies successfully establish the proof of concept that our vaccine thermostabilization technology works and now allows for the potential to apply this technology to other conventional vaccines that require refrigeration.

The lyophilized vaccine was kept at 40 degrees Celsius for more than one month and was then used to vaccinate animals. The vaccine developed high titer and potent neutralizing antibodies. By creating vaccines that can handle higher and more variable temperatures, the profitability and utility of vaccine products would be greatly improved.

"Cold chain requirements add considerable cost to the production and storage of current conventional vaccines," Brey said. "Further, lack of long-term stability is a significant problem in vaccines for use in emergency situations and especially for vaccines used in the developing world where the cold storage chain is difficult to maintain. We believe that this technology has the potential to add value to many existing and developing vaccines."